KFF: Insurers Denied 12%-18% of Prior Authorization Requests in 2025
KFF found that insurers denied 12%-18% of standard prior authorization requests in 2025, with significant…
KFF: Insurers Denied 12%-18% of Prior Authorization Requests in 2025
KFF found that insurers denied 12%-18% of standard prior authorization requests in 2025, with significant variation among insurers and gaps in transparency. The post KFF: Insurers Denied 12%-18% of Prior Authorization Requests in 2025 appeared first on MedCity News.
Slate Medicines’ Merger and $245M Private Placement Fuel Mission in Migraine
Migraine drugs developer Slate Medicines is going public in a reverse merger with Fulcrum Therapeutics. The biotech’s lead antibody drug blocks two novel migraine targets, offering the potential for better efficacy compared to other next-generation migraine drugs in R&D. The post Slate Medicines’ Merger and $245M Private Placement Fuel Mission in Migraine appeared first on…
The Rise of Consumer Diagnostics and Emerging Trends
Consumer diagnostics will be one of several discussions at the INVEST Digital Health conference focused on power shifting to the consumer in healthcare. The conference is scheduled for October 29 in Dallas at Pegasus Park, in partnership with Health Wildcatters. Click here to view the agenda and register. The post The Rise of Consumer Diagnostics…
Healthcare Is Deploying AI Tools — It’s Not Ready for AI Colleagues
Most healthcare organizations are experimenting with AI. Few are preparing to manage AI agents as participants in everyday healthcare workflows. The post Healthcare Is Deploying AI Tools — It’s Not Ready for AI Colleagues appeared first on MedCity News.
How Payers and Health Plans Think of Identity and the Risks of Fragmented Data
[Sponsored] A recent webinar, sponsored by Verato, offered insights from executives at SCAN Health Plan and the Alliance of Community Health Plans on a wide range of tech challenges in healthcare from fragmented data to technology architecture to patient identity. The post How Payers and Health Plans Think of Identity and the Risks of Fragmented…
Newsom Promotes Affordable Insulin, but California’s Generic Label Off to a Slow Start
SAN FRANCISCO — At a Walgreens in this city’s bustling Japantown neighborhood, pharmacist Margaret On stocks two boxes of long-acting insulin pens from California’s new prescription drug label, CalRx, emblazoned with the state’s iconic grizzly bear. Although she hasn’t dispensed any, On plans to keep them on hand. “It’s good to have if a patient…
Kennedy’s Quiet Hunt for Autism Culprits Stalls as Trump Orders Baseless Changes to Childhood Shots
President Donald Trump has ordered a reduction in childhood vaccines — publicly faulting the shots for an increase in autism cases — even as the nation’s top health official, Robert F. Kennedy Jr., has failed to produce evidence linking vaccinations to the disorder. While the executive order released Aug. 10 does not directly mention autism,…
Pre-Surgical Complications (Part 6) — The Decision
By MATTHEW HOLT Strap in for the tale of why your hero is spending most of his life down YouTube rabbit holes of cardiology videos while blundering his way around many many medical centers and exposing many problems with American health care even before he gets close to the operating table. Yes it’s Matthew Holt’s…
The Reimbursement Challenges Hurting Women’s Health Companies, Per Milken Institute
Women’s health startups should plan for reimbursement early, as limited research and evidence can make securing coverage difficult, a new report explains. The post The Reimbursement Challenges Hurting Women’s Health Companies, Per Milken Institute appeared first on MedCity News.
Vogenx IPO Raises $81M for Trial in Metabolic Disease With No Approved Drugs
Vogenx’s mizagliflozin is heading into Phase 2b testing for post-bariatric hypoglycemia (PBH). Amylyx Pharmaceuticals and Recordati are developing injectable peptide drugs for this metabolic disorder, but Vogenx aims to stand apart by offering patients a different mechanism of action and oral dosing. The post Vogenx IPO Raises $81M for Trial in Metabolic Disease With No…
